These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 21883686

  • 1. Individualized long-term enzyme therapy for Gaucher disease type 1 in Slovenia.
    Benedik-Dolničar M, Kitanovski L.
    Pediatr Int; 2011 Dec; 53(6):1018-22. PubMed ID: 21883686
    [Abstract] [Full Text] [Related]

  • 2. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
    Andersson H, Kaplan P, Kacena K, Yee J.
    Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
    [Abstract] [Full Text] [Related]

  • 3. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 4. Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease.
    Zimran A, Wang N, Ogg C, Crombez E, Cohn GM, Elstein D.
    Am J Hematol; 2015 Jul; 90(7):577-83. PubMed ID: 25903392
    [Abstract] [Full Text] [Related]

  • 5. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R, Arndt S, Levin JB.
    S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
    [Abstract] [Full Text] [Related]

  • 6. Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials.
    Hughes DA, Gonzalez DE, Lukina EA, Mehta A, Kabra M, Elstein D, Kisinovsky I, Giraldo P, Bavdekar A, Hangartner TN, Wang N, Crombez E, Zimran A.
    Am J Hematol; 2015 Jul; 90(7):584-91. PubMed ID: 25801797
    [Abstract] [Full Text] [Related]

  • 7. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.
    van Dussen L, Hendriks EJ, Groener JE, Boot RG, Hollak CE, Aerts JM.
    J Inherit Metab Dis; 2014 Nov; 37(6):991-1001. PubMed ID: 24831585
    [Abstract] [Full Text] [Related]

  • 8. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
    Tóth J, Szücs FZ, Benkö K, Maródi L.
    Orv Hetil; 2003 Apr 20; 144(16):749-55. PubMed ID: 12778625
    [Abstract] [Full Text] [Related]

  • 9. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
    Amato D, Patterson MA.
    J Med Case Rep; 2018 Jan 27; 12(1):19. PubMed ID: 29373994
    [Abstract] [Full Text] [Related]

  • 10. Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up.
    Elstein D, Haims AH, Zahrieh D, Cohn GM, Zimran A.
    Blood Cells Mol Dis; 2014 Jan 27; 53(1-2):56-60. PubMed ID: 24581483
    [Abstract] [Full Text] [Related]

  • 11. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 27; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 12. Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease.
    Erikson A, Forsberg H, Nilsson M, Aström M, Månsson JE.
    Acta Paediatr; 2006 Mar 27; 95(3):312-7. PubMed ID: 16497642
    [Abstract] [Full Text] [Related]

  • 13. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
    Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW.
    Blood Cells Mol Dis; 2000 Aug 27; 26(4):285-90. PubMed ID: 11042029
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D, Mehta A, Hughes DA, Giraldo P, Charrow J, Smith L, Shankar SP, Hangartner TN, Kunes Y, Wang N, Crombez E, Zimran A.
    Am J Hematol; 2015 Jul 27; 90(7):592-7. PubMed ID: 25776130
    [Abstract] [Full Text] [Related]

  • 15. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
    Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MF, Elstein D, Zahrieh D, Crombez E, Bhirangi K, Barton NW, Zimran A.
    Am J Hematol; 2013 Mar 27; 88(3):166-71. PubMed ID: 23386328
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.
    Laudemann K, Moos L, Mengel E, Lollert A, Hoffmann C, Brixius-Huth M, Wagner D, Düber C, Staatz G.
    Blood Cells Mol Dis; 2016 Mar 27; 57():35-41. PubMed ID: 26852653
    [Abstract] [Full Text] [Related]

  • 17. Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India.
    Nagral A, Mewawalla P, Jagadeesh S, Kabra M, Phadke SR, Verma IC, Puri RD, Gupta N, Kishnani PS, Mistry PK.
    Indian Pediatr; 2011 Oct 27; 48(10):779-84. PubMed ID: 22080680
    [Abstract] [Full Text] [Related]

  • 18. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
    Weinreb NJ, Camelo JS, Charrow J, McClain MR, Mistry P, Belmatoug N, International Collaborative Gaucher Group (ICGG) Gaucher Registry (NCT00358943) investigators.
    Mol Genet Metab; 2021 Feb 27; 132(2):100-111. PubMed ID: 33485799
    [Abstract] [Full Text] [Related]

  • 19. The effect of enzyme therapy in a patient with Gaucher disease type III.
    Bosman DK, Hollak CE, Aerts JM, Bakker HD.
    J Inherit Metab Dis; 1996 Feb 27; 19(5):703-4. PubMed ID: 8892032
    [No Abstract] [Full Text] [Related]

  • 20. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.
    Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A.
    Am J Med; 2002 Aug 01; 113(2):112-9. PubMed ID: 12133749
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.